Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
1.355
+0.025 (1.88%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases.

Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration.

The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011.

Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc.
Galectin Therapeutics logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Joel Lewis

Contact Details

Address:
4960 Peachtree Industrial Boulevard, Suite 240
Norcross, Georgia 30071
United States
Phone 678 620 3186
Website galectintherapeutics.com

Stock Details

Ticker Symbol GALT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001133416
CUSIP Number 363225202
ISIN Number US3632252025
Employer ID 04-3562325
SIC Code 2834

Key Executives

Name Position
Joel Lewis CPA President, Chief Executive Officer and Director
Jack W. Callicutt CPA Chief Financial Officer, Treasurer and Corporate Secretary
Dr. Khurram Jamil M.D. Chief Medical Officer
Robert Tritt J.D. General Counsel
Jeff Katstra Head of CMC and Pharmaceutical Development
Beth Knowles Executive Assistant and Officer Manager

Latest SEC Filings

Date Type Title
Mar 31, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Mar 5, 2025 8-K Current Report
Feb 18, 2025 8-K Current Report
Jan 28, 2025 8-K Current Report
Jan 23, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report
Dec 23, 2024 144 Filing
Dec 23, 2024 144 Filing
Dec 23, 2024 144 Filing